News

CHAPEL HILL, N.C., Jan. 12, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today announced that it has completed its previously announced underwritten public offering of 4,166,667 shares of its common stock at a price of $24.00 per share. Net proceeds after underwriting discounts and commissions and expenses of the offering are expected to be approximately $93.7 million. The company also has granted the underwriters a 30-day option to purchase up to an additional 625,000 shares, which would result in additional net proceeds of approximately $14.1 million, if exercised in full.

CLEVELAND, January 11, 2016 — ViewRay, Inc. (OTCQB: VRAY) announced today the two-year anniversary of treating patients with MRI-guided radiation therapy at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, Mo.

NEW YORK-- Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced positive phase 1b data with its second uroguanylin analog, dolcanatide, in a double-blind, placebo-controlled, four-week study evaluating 28 patients with mild-to-moderate ulcerative colitis. Analysis of the data indicates clear signals of improvement in dolcanatide-treated patients compared with placebo-treated patients. Dolcanatide was also safe and well tolerated.

— Aimmune Provides Year-End Update and Upcoming Milestones Review — BRISBANE, Calif.--(BUSINESS WIRE)--Jan. 11, 2016-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing desensitization treatments for food allergies, announced today that it has enrolled the first patient in the pivotal Phase 3 PALISADE trial of its lead product candidate, AR101 for the treatment of peanut allergy. More than five million people in the United States and Europe have peanut allergy, an increasingly prevalent, potentially life-threatening, chronic condition for which there are no approved treatments.

-- Multiple Ascending Dose Study-Results Reinforce Excellent Safety and Tolerability – SAN DIEGO--(BUSINESS WIRE)--Jan. 11, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives and immunotherapies to treat fungal and other infections, today announced data from the company’s Phase 1 multiple ascending dose clinical trial of its antifungal drug candidate, CD101 IV, in healthy volunteers. CD101 IV is a novel, long-acting echinocandin that Cidara is developing for the treatment and prevention of serious, invasive fungal infections, including candidemia and invasive candidiasis.

Enrollment for All Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Plaque Psoriasis Completed Dermira Plans to Announce Topline Data for Phase 3 Trials by End of First Quarter 2017 MENLO PARK, Calif., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the completion of patient enrollment for the CIMPACT clinical trial of CIMZIA® (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis. The CIMPACT study is the third and final clinical trial of the CIMZIA Phase 3 development program in moderate-to-severe chronic plaque psoriasis to complete enrollment, following the completion of enrollment for the CIMPASI-2 Phase 3 trial in September 2015 and CIMPASI-1 Phase 3 trial in November 2015. CIMZIA is not currently approved for the treatment of psoriasis by any regulatory authority worldwide.

Pivotal trial of Cynapsus’ under-the-tongue apomorphine formulation will include technology-enabled sub-study to gather and analyze objective patient data on disease progression and medication effect Effort builds on ongoing data science collaboration between Michael J. Fox Foundation and Intel Corporation TORONTO, NEW YORK, Jan. 7, 2016 – Cynapsus Therapeutics Inc. (NASDAQ: CYNA) (TSX: CTH) and The Michael J. Fox Foundation for Parkinson’s Research (“MJFF”) today announced that they are working together to incorporate wearable device technology and “big data” approaches into Cynapsus’ pivotal Phase 3 clinical study of APL-130277, a sublingual (under-the-tongue) formulation of apomorphine to treat (“OFF”) episodes in Parkinson’s disease (“PD”) patients.

BOSTON, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) to report top-line data in mid-2016. The company had previously estimated that this trial would report top-line data in the second half of 2016. The revised estimate reflects to date better-than-anticipated enrollment performance in the trial. This trial, which is designed to assess the efficacy and safety of once-daily oral and intravenous formulations of omadacycline compared to linezolid in ABSSSI, enrolled its first patient in June 2015. In November 2015, Paratek initiated enrollment of a Phase 3 trial of oral and IV omadacycline for community acquired bacterial pneumonia (CABP).

NEW YORK, Jan. 5, 2016 /PRNewswire/ -- Aisling Capital, a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies, announced that Eric Aguiar, MD has joined the firm as a Partner. Dr. Aguiar, who brings to Aisling experience in drug development, commercialization and strategic leadership, will invest in biopharma opportunities across a range of therapeutic areas and stages of development.

In-Market Activity Educates Consumers on the Noninvasive Fat Reduction Procedure and Drives Local Practice Success PLEASANTON, CA -- (Marketwired) -- 12/28/15 -- ZELTIQ® Aesthetics, Inc. (NASDAQ: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the launch of its national advertising campaign that encourages consumers to Fear No Mirror® with the CoolSculpting® procedure.